These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 26751497)

  • 21. Plasma filtration for the controlled removal of liposomal therapeutics - From the apheretic site of view.
    Blaha M; Martinkova J; Lanska M; Filip S; Malakova J; Kubecek O; Bezouska J; Spacek J
    Atheroscler Suppl; 2017 Nov; 30():286-293. PubMed ID: 29096853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Doxorubicin Delivery Systems and Mild Hyperthermia on Tissue Penetration in 3D Cell Culture Models of Ovarian Cancer Residual Disease.
    Eetezadi S; De Souza R; Vythilingam M; Lessa Cataldi R; Allen C
    Mol Pharm; 2015 Nov; 12(11):3973-85. PubMed ID: 26394060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients.
    Kubeček O; Bláha M; Diaz-Garcia D; Filip S
    Acta Medica (Hradec Kralove); 2015; 58(1):3-8. PubMed ID: 26454800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.
    Gabizon AA; Patil Y; La-Beck NM
    Drug Resist Updat; 2016 Nov; 29():90-106. PubMed ID: 27912846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential intracellular processing of the anthracycline drug ME2303 in doxorubicin-sensitive (A2780) and -resistant (A2780AD) human ovarian cancer cells as studied with confocal laser scanning microscopy and image analysis.
    Huxham IM; Barlow AL; Lewis AD; Plumb J; Mairs RJ; Gaze MN; Workman P
    Int J Cancer; 1994 Oct; 59(1):94-102. PubMed ID: 7927910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crocin suppresses multidrug resistance in MRP overexpressing ovarian cancer cell line.
    Mahdizadeh S; Karimi G; Behravan J; Arabzadeh S; Lage H; Kalalinia F
    Daru; 2016 Jun; 24(1):17. PubMed ID: 27342070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid rafts clustering and signalling by listeriolysin O.
    Gekara NO; Weiss S
    Biochem Soc Trans; 2004 Nov; 32(Pt 5):712-4. PubMed ID: 15493995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bypassing multidrug resistant ovarian cancer using ultrasound responsive doxorubicin/curcumin co-deliver alginate nanodroplets.
    Baghbani F; Moztarzadeh F
    Colloids Surf B Biointerfaces; 2017 May; 153():132-140. PubMed ID: 28235723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas.
    Amin M; Badiee A; Jaafari MR
    Int J Pharm; 2013 Dec; 458(2):324-33. PubMed ID: 24148663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytosolic delivery of antisense oligonucleotides by listeriolysin O-containing liposomes.
    Mathew E; Hardee GE; Bennett CF; Lee KD
    Gene Ther; 2003 Jul; 10(13):1105-15. PubMed ID: 12808441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.
    Kavanagh JJ; Levenback CF; Ramirez PT; Wolf JL; Moore CL; Jones MR; Meng L; Brown GL; Bast RC
    J Hematol Oncol; 2010 Mar; 3():9. PubMed ID: 20222977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
    Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
    Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced antitumor activity of different double arms polyethyleneglycol-modified liposomal doxorubicin.
    Sugiyama I; Sadzuka Y
    Int J Pharm; 2013 Jan; 441(1-2):279-84. PubMed ID: 23194885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
    Arabi L; Badiee A; Mosaffa F; Jaafari MR
    J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin.
    Provoda CJ; Stier EM; Lee KD
    J Biol Chem; 2003 Sep; 278(37):35102-8. PubMed ID: 12832408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel amiodarone-doxorubicin cocktail liposomes enhance doxorubicin retention and cytotoxicity in DU145 human prostate carcinoma cells.
    Theodossiou TA; Galanou MC; Paleos CM
    J Med Chem; 2008 Oct; 51(19):6067-74. PubMed ID: 18783209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
    Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
    J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
    Yang Y; Yang Y; Xie X; Cai X; Zhang H; Gong W; Wang Z; Mei X
    Biomaterials; 2014 May; 35(14):4368-81. PubMed ID: 24565519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.